Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 105

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 105
---
,789,627)90 %Total direct program costs907,863 3,614,895 (2,707,032)(75)%Indirect costs:Personnel-related (including stock compensation)1,209,437 1,482,550 (273,113)(18)%Outside services (including consulting)(8,839)1,687 (10,526)(624)%Facilities-related (including depreciation)18,516 20,228 (1,712)(8)%Other indirect R&D costs60,785 60,063 722 1 %Contra R&D expenses(759,000)(245,649)(513,351)209 %Total indirect R&D costs520,899 1,318,879 (797,980)(61)%Total R&D expenses$1,428,762 $4,933,774 $(3,505,012)(71)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (2) below. 2.These contra R&D expenses were recognized as follows for the three months ended June 30, 2025 and 2024: (a) Ovaprene, $0.4 million, and $0, respectively; (b) other advanced clinical stage programs, $1.0 million and $0 respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0.1 million and $0.3 million, respectively; and (d) preclinical stage programs, $2.2 million and $1.7 million, respectively.

The decrease of approximately $3.5 million in R&D expenses for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024 was primarily attributable to (i) an increase in contra R&D expenses, (ii) a decrease in manufacturing costs related to Ovaprene, and (iii) a decrease in costs related to development activities for Sildenafil Cream, partially offset by increases in costs related to development activities for (A) our other advanced clinical stage programs - primarily attributable to our DARE-HPV program, (B) our Phase 1 and Phase 1-ready clinical stage programs - primarily attributable to our D